FDA Issues Warning to New Jersey Developer for Marketing Unapproved Stem Cell Product – Rare Disease Report
The Pharma Letter |
FDA Issues Warning to New Jersey Developer for Marketing Unapproved Stem Cell Product
Rare Disease Report “We see great promise from the field of cell based regenerative medicine, but there are also novel risks,” continued Gottlieb. “Our goal is to implement our new policy framework in a way that helps this promising field advance, while making sure that … FDA Crackdown on Unapproved Stem Cell Therapies Starts with American CryoStem FDA warning on sale of unapproved stem cell product FDA Issues Warning Over Unapproved Stem Cell Therapies |
